Correlation Between Tcr2 Therapeutics and Black Diamond

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Tcr2 Therapeutics and Black Diamond at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Tcr2 Therapeutics and Black Diamond into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Tcr2 Therapeutics and Black Diamond Therapeutics, you can compare the effects of market volatilities on Tcr2 Therapeutics and Black Diamond and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Tcr2 Therapeutics with a short position of Black Diamond. Check out your portfolio center. Please also check ongoing floating volatility patterns of Tcr2 Therapeutics and Black Diamond.

Diversification Opportunities for Tcr2 Therapeutics and Black Diamond

-0.68
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Tcr2 and Black is -0.68. Overlapping area represents the amount of risk that can be diversified away by holding Tcr2 Therapeutics and Black Diamond Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Black Diamond Therap and Tcr2 Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Tcr2 Therapeutics are associated (or correlated) with Black Diamond. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Black Diamond Therap has no effect on the direction of Tcr2 Therapeutics i.e., Tcr2 Therapeutics and Black Diamond go up and down completely randomly.

Pair Corralation between Tcr2 Therapeutics and Black Diamond

Given the investment horizon of 90 days Tcr2 Therapeutics is expected to under-perform the Black Diamond. But the stock apears to be less risky and, when comparing its historical volatility, Tcr2 Therapeutics is 4.61 times less risky than Black Diamond. The stock trades about -0.55 of its potential returns per unit of risk. The Black Diamond Therapeutics is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  182.00  in Black Diamond Therapeutics on August 31, 2024 and sell it today you would earn a total of  75.00  from holding Black Diamond Therapeutics or generate 41.21% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy4.57%
ValuesDaily Returns

Tcr2 Therapeutics  vs.  Black Diamond Therapeutics

 Performance 
       Timeline  
Tcr2 Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Tcr2 Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Tcr2 Therapeutics is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors.
Black Diamond Therap 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Black Diamond Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Tcr2 Therapeutics and Black Diamond Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Tcr2 Therapeutics and Black Diamond

The main advantage of trading using opposite Tcr2 Therapeutics and Black Diamond positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Tcr2 Therapeutics position performs unexpectedly, Black Diamond can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Black Diamond will offset losses from the drop in Black Diamond's long position.
The idea behind Tcr2 Therapeutics and Black Diamond Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Other Complementary Tools

USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Stocks Directory
Find actively traded stocks across global markets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm